Last reviewed · How we verify
NCT06132035
Phase I Clinical Study to Evaluate the Safety of CG-P5 Peptide Eye Drops (Self-administered and Topically Applied) in Patients Diagnosed With Age-related Wet Macular Degeneration
Phase 1 trial testing CG-P5 peptide in Age-related Wet Macular Degeneration in 45 participants. Currently enrolling.
1 May 2025
Quick facts
| Lead sponsor | Caregen Co. Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 22 December 2023 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 August 2025 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- CG-P5 peptide — full drug profile →
- Placebo
- Aflibercept Injection [Eylea] — full drug profile →
Conditions studied
- Age-related Wet Macular Degeneration — all drugs for Age-related Wet Macular Degeneration →
Sponsor
Caregen Co. Ltd. — full company profile →
Who can join
50 and older, any sex, with Age-related Wet Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The percentage of occurrence of Adverse Events (AE)
Time frame: Screening, Day 0, Day 28, Day 56 & Day 84 -
The number of Adverse Events (AE) that occurs
Time frame: Screening, Day 0, Day 28, Day 56 & Day 84 -
Change in IOP with study drug compared to placebo
Time frame: Screening, Day 0, Day 28, Day 56 & Day 84
Mean change in intraocular pressure (IOP) with study drug compared to placebo from baseline to end of study -
Change in intraocular inflammation with study drug compared to placebo
Time frame: Screening, Day 0, Day 28, Day 56 & Day 84
Mean change in intraocular inflammation with study drug compared to placebo from baseline to end of study -
Incidence and severity of ocular and non-ocular adverse events of CG-P5 peptide eye drops and Placebo
Time frame: Day 0, Day 28, Day 56 & Day 84
Mean change in incidence and severity of ocular and non-ocular adverse events of CG-P5 peptide eye drops and Placebo with study drug compared to placebo from baseline to end of study
Sponsor's own description
This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06132035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06132035 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Caregen Co. Ltd.
- Last refreshed: 5 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06132035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing